Form 4: Trevi CFO Granted 375,000 Stock Options

Trevi Therapeutics' Chief Financial Officer, David C. Hastings, was granted 375,000 stock options with an exercise price of $11.21, vesting over four years.

Summary

• David C. Hastings, Chief Financial Officer of Trevi Therapeutics, Inc. (TRVI), was granted 375,000 stock options.
• The options have an exercise price of $11.21 per share.
• The grant date for these options was January 8, 2026.
• The options are scheduled to vest as to 25% of the shares on January 8, 2027, and the remaining 75% in equal monthly installments thereafter through January 8, 2030.
• The expiration date for the options is January 7, 2036.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a routine corporate action aimed at aligning management incentives with shareholder interests over the long term. It reflects standard compensation practices and a commitment to retaining leadership.

Positives

• The grant of 375,000 stock options to the Chief Financial Officer aligns management's interests with shareholder value creation.
• The vesting schedule over several years encourages long-term commitment and performance from the executive.

Negatives

• No direct negatives are reported in this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The vesting schedule for the stock options, extending through January 8, 2030, indicates a long-term incentive structure designed to retain the Chief Financial Officer and align their performance with the company's sustained growth and shareholder value creation over several years.

Industry Context

Granting stock options to key executives like the Chief Financial Officer is a standard practice in the biotechnology and pharmaceutical industries, including companies like Trevi Therapeutics. This compensation strategy is widely used to attract, retain, and motivate top talent by linking their personal financial success to the company's stock performance, thereby aligning executive interests with those of shareholders.

Comparison to Industry Standards

• The grant of stock options as a form of executive compensation is a common practice across the biotechnology and pharmaceutical sectors, similar to companies such as BioNTech, Moderna, or Gilead Sciences, which frequently utilize equity incentives to attract and retain key personnel.
• The vesting schedule, with an initial 25% vesting after one year and the remainder over subsequent years, is typical for long-term incentive plans in the industry, promoting sustained performance and executive retention.
• The exercise price of $11.21, presumably the market price on the grant date, is standard for at-the-money option grants, ensuring the executive benefits only if the stock price appreciates.

Corporate Governance

Related Party Transactions

• This filing reports an executive compensation event, which is a transaction with a related party (an officer), but it is a standard, disclosed compensation mechanism rather than an unusual related-party transaction.

Stakeholder Impact

• Shareholders: The option grant aims to align the Chief Financial Officer's interests with shareholder value creation, potentially leading to improved long-term performance. However, it also represents potential future dilution if options are exercised.
• Employees: May view this as a standard executive incentive, potentially impacting morale positively by demonstrating commitment to leadership.

Next Steps

• The stock options will begin vesting on January 8, 2027, with subsequent monthly vesting through January 8, 2030.
• David C. Hastings may exercise the vested options at any time before the expiration date of January 7, 2036.

Key Dates

Keywords

Trevi Therapeutics, TRVI, Stock Option, Executive Compensation, Insider Transaction, Form 4, David C. Hastings, Chief Financial Officer